

## **Letter from the Chairman of the Supervisory Board**

Mainz, April 8, 2026

Letter from the Chairman of the Supervisory Board

Dear Shareholders,

2025 was a successful year for BioNTech. We have taken decisive steps to bring the Company closer to its goal of becoming a multi-product company by 2030. Today, BioNTech stands on a strong foundation – strategically and financially. Last year's key achievements include the partnership with Bristol Myers Squibb (BMS), the acquisition of Biotheus and the continued leadership of Comirnaty in the COVID-19 vaccine market. With its robust cash position BioNTech is well-equipped to continue its successful development in 2026.

In March 2026 we announced that, after 18 years of building BioNTech, CEO Prof. Ugur Sahin, M.D., and CMO Prof. Özlem Türeci, M.D., will pass on the baton and leave the Company by the end of this year. With its unique oncology pipeline, successful strategic acquisitions and partnerships and a clear strategy going forward, BioNTech is ready to move into its next phase. We are deeply grateful to Ugur Sahin and Özlem Türeci, and we will continue to work closely together with their new company.

### **A Long-Term Strategy After the COVID-19 pandemic**

BioNTech is in today's position because it has been diligently following a long-term strategy that has started to take shape after the success of its first commercial product. Shortly after the first successful years with Comirnaty, BioNTech set out clear strategic priorities to guide the next chapter of the Company and the ambition to become a multi-product company by 2030.

BioNTech's vision is clear: Translating science into survival, with a focus on oncology. In the past couple of years, the Company has focused on building its pipeline through internal and external innovation, including strategic business development and licensing as well as mergers and acquisitions. The in-licensing deal of pumitamid, and the subsequent acquisition of Biotheus, also including its pipeline with early-stage candidates, is just one example of this focus. BioNTech has identified its lead assets with the potential of becoming backbone therapies advancing the current standard of care for many patients across various solid tumor types.

Pumitamid is one of our lead assets. Together with BMS, BioNTech expects to have eight global Phase 3 clinical trials ongoing by the end of this year, showing the candidate's disruptive potential in the oncology treatment landscape.

Given the exceptional development of BioNTech and our goal to exploit the full potential, the Company will further optimize its approach to capital allocation, risk-based decision making and operational excellence.

### **Entering the Commercialization Phase from a Position of Strength**

BioNTech enters this next phase with strong momentum. We see multiple opportunities to create meaningful, long-term value by bringing highly innovative oncology products to patients worldwide. BioNTech's partnership with BMS is both of strategic and operational importance for pumitamid. It enables BioNTech to develop this lead candidate broader and faster, while ensuring we keep a close eye on our other opportunities. It allows BioNTech to build a commercial organization in a measured, yet sustainable way.

With cash and security investments on the balance sheet of EUR 17.2 bn at the end of 2025, BioNTech has the resources needed to invest in the next phase of growth. At the same time, we see it as essential that BioNTech maintains a disciplined approach to resource allocation. In addition, the Supervisory Board and Management Board continue to assess measures that enable us to return capital to shareholders while retaining the flexibility to pursue attractive growth opportunities.

### **Complementing Expertise for BioNTech's Next Phase of Growth**

The Management Board has been further strengthened with capabilities that are critical for the upcoming commercialization and scaling phase. Ramón Zapata was appointed Chief Financial Officer in July 2025 and Kylie Jimenez Chief People Officer in March 2026. As part of the planned transition following the departure of Ugur Sahin and Özlem Türeci, by the end of 2026, the Supervisory Board has initiated a thorough, international search for their successors aimed at identifying the best possible candidates to lead BioNTech through this next phase.

The evolution of the Company is also reflected at Supervisory Board level. We intend to complement the Supervisory Board with expertise in clinical development as well as in sales and commercialization. We therefore propose expanding the Supervisory Board from six to eight members. For the new seats, we propose the election of Susanne Schaffert, Ph.D. and Prof. Iris Loew-Friedrich, M.D. Both candidates possess a deep understanding of the biopharmaceutical market and the Company's key clinical development phases. To ensure continuity and experience, we also propose the re-election of Prof. Anja Morawietz, Ph.D. and Prof. Rudolf Staudigl, Ph.D. I will also stand for re-election to continue supporting BioNTech beyond 2026.

In addition, we ask for your approval of renewed authorized capital. The existing authorization has been successfully used for an important strategic step, the acquisition of CureVac. The new authorized capital is intended to ensure that BioNTech continues to have the necessary financial flexibility to capture growth opportunities. The proposal provides for an authorization

amounting to 50% of the share capital, whereby we have voluntarily committed to limiting the exclusion of subscription rights to a maximum of 10%, thereby particularly safeguarding your interests as shareholders.

These agenda items will be presented at our virtual Annual General Meeting on May 15, 2026, to which I cordially invite you. The virtual format has proven to be effective and resource efficient and is particularly suitable for our international shareholder base. We therefore propose extending the authorization to hold virtual Annual General Meetings for two years.

With our attractive pipeline spanning lead assets and early candidates including newly acquired assets from Biotheus, strong partners, and a robust financial position, BioNTech has never been in a better position to deliver on its mission in oncology and to evolve into a multi-product company by 2030 to deliver value for patients and shareholders.

Thank you for your continued trust in BioNTech.

Yours sincerely,

Helmut Jeggle

Chairman of the Supervisory Board of BioNTech SE